RL34 Subgroup Claim: When to Accept?
*Rajeshwari Sridhara, U.S. Food and Drug Administration Keywords: Subgroup analyses are conducted routinely whether they are specified in the protocol or not. The results from such analyses become contentious particularly if the primary analysis in all randomized patients has not demonstrated efficacy. This roundtable will discuss the pros and cons of subgroup analyses when they were (1) planned vs. not planned, (2) observed in one study vs. multiple studies, and (3) in non-inferiority vs. superiority studies.
|
Key Dates
-
April 30 - May 22, 2013
Invited Abstract Submission Open -
June 4, 2013
Online Registration Opens -
August 9 - August 23, 2013
Invited Abstract Editing -
August 23, 2013
Short Course materials due from Instructors -
August 26, 2013
Housing Deadline -
September 9, 2013
Cancellation Deadline and Registration Closes @ 11:59 pm EDT -
September 16 - September 18, 2013
Marriott Wardman Park, Washington, DC